Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
NCT00313001 on ClinicalTrials.gov · last registry update 2017-01-06
Finished July 2007, after enrolling 373 people. Primary outcome, as filed: Superiority as assessed by HbA1c reduction. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 373
- Started
- 2006-04
- Primary completion
- 2007-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Superiority as assessed by HbA1c reduction
Conditions studied
Diabetes · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.